In this issue of Blood, Giles and colleagues report the remarkable clinical activity of MK-0457, an aurora kinase inhibitor, in 3 Philadelphia chromosome-positive leukemia patients harboring the highly resistant T315I mutation.
Martinelli, G., Soverini, S., Iacobucci, I., Baccarani, M. (2007). MK-0457: a light at the end of the tunnel?. BLOOD, 109(2), 396-397 [10.1182/blood-2006-10-049320].
MK-0457: a light at the end of the tunnel?
MARTINELLI, GIOVANNI;SOVERINI, SIMONA;IACOBUCCI, ILARIA;BACCARANI, MICHELE
2007
Abstract
In this issue of Blood, Giles and colleagues report the remarkable clinical activity of MK-0457, an aurora kinase inhibitor, in 3 Philadelphia chromosome-positive leukemia patients harboring the highly resistant T315I mutation.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
